Vector Capital to Acquire Showpad
26.8.2025 22:00:00 CEST | Business Wire | Press release
Will Combine Showpad and Bigtincan Into a Global Leader in the Revenue Enablement Market Growing to $12B in 20301
Vector Capital Management, L.P., a leading private equity firm specializing in transformational investments in established technology businesses, today announced an agreement to acquire Showpad, a leader in AI revenue enablement technology with headquarters in Chicago and Ghent, Belgium.
Customers in over 50 countries —including Coca-Cola, Dow, DuPont, GE Healthcare, Kaiser Permanente and Schneider Electric — leverage Showpad to bring together marketing and revenue teams to engage buyers and add value at every interaction. The company is a Forrester Wave™ leader in multiple categories2, and a “Customers’ Choice” for Revenue Enablement Platforms3 on Gartner® Peer Insights™.
After the transaction closes, Vector will combine Showpad with Bigtincan Holdings, which it acquired in April 2025. The combined entity will operate under the Showpad brand. It will deliver a complete AI-powered revenue enablement solution across all aspects of buyer-seller engagement with broad geographic diversity, and combined R&D resources to accelerate innovation market-wide.
Bigtincan is a five-time leader in The Aragon Research Globe™for Sales Enablement Platforms and has received multiple awards for AI and other innovations. Over 1,000 companies — including Abbott, AT&T, Clorox, Merck, Winnebago, and 100 of the Fortune 500 — use Bigtincan’s AI-powered sales enablement solutions to augment, automate and modernize seller and buyer engagement.
“The combination of Bigtincan with Showpad brings together best-in-class innovation and market leaders with thousands of customers,” said Amish Mehta, Chief Investment Officer and Managing Director at Vector Capital. “The combined company will lead the digital and AI-fueled buyer and seller engagement and drive a new generation of experiences that people and brands love.”
Insight Partners, a large investor in Showpad, will roll over its full investment into the combined company. The completion of the transaction is subject to customary conditions, including regulatory approval. Further terms were not disclosed, and the transaction is expected to close in 2025.
Watershed Moment in AI-Powered Revenue Enablement Market
“The merger of Showpad and Bigtincan represents a watershed moment for the sales enablement market,” said Jim Lundy, Founder and Lead Analyst at Aragon Research. “By uniting complementary strengths in content, readiness, and AI, the combined company is poised to deliver on the market's unmet demand for AI-centric sales enablement platforms that are easier to deploy, simpler to use and more impactful for revenue teams worldwide."
“Our unwavering focus on driving success for customers fueled a record-breaking year of growth for Showpad in 2024,” said Hendrik Isebaert, CEO of Showpad. “Together we will deliver a breadth of flexible solutions and an incredible team to help customers engage with buyers in new and creative ways they never thought possible.”
“Evolving preferences and rapid technology advancements are aggressively transforming buying and selling behaviors,” said Jim Hopkins, Chairman of Bigtincan. “We invested early and heavily in AI, and our combined global R&D resources will accelerate innovation so customers can rapidly reap the benefits of AI and emerging future innovations.”
Sidley Austin LLP is serving as legal counsel, Deloitte LLP is serving as tax advisor and Alvarez & Marsal is serving as financial advisor to Vector Capital. Cleary Gottlieb Steen & Hamilton LLP is acting as legal counsel and TD Securities is acting as financial advisor to Showpad.
“Vector Capital has a long history of building category-defining technology companies,” said Rob Amen, Managing Director at Vector Capital. “Both companies bring impressive industry expertise and commitment to excellence. Together, they will continue to drive the future and set industry standards and best practices globally.”
For more, visit our acquisition information page and follow Bigtincan, Showpad and Vector Capital on LinkedIn.
About Vector Capital Management, L.P.
Vector Capital is a leading San Francisco-based investment firm focused on transformational investments in middle-market technology and technology-enabled businesses. Founded in 1997, Vector manages over $4 billion of capital across credit and private equity strategies on behalf of a high-quality group of global limited partners. For nearly 28 years, Vector has combined technology investments with operational transformation to deliver breakthrough results. For more information, visit www.vectorcapital.com.
1 Grand View Research, Sales Enablement Platform Market Size Report, 2030. | |
2 Forrester Wave™: Revenue Enablement Platforms, Q3 2024, and Sales Readiness Solutions, Q4 2023 reports. | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250826870353/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom